ANVISA has clarified when a smart ring crosses toward medical-device regulation
ANVISA published a fact-checking notice on August 27, 2026 addressing smart rings and health-related claims.
The Agency states that smart rings currently available on the market should not be used to diagnose diseases.
Many of these products are positioned by manufacturers as wellness or sports accessories. Where they do not have a medical intended purpose and do not measure physiological parameters typically used for clinical purposes, they are generally not treated as medical products requiring ANVISA regularization.
Diagnostic and clinical-measurement claims change the regulatory picture
The distinction becomes more important when a product is promoted for diagnosis or clinical measurement.
ANVISA specifically states that products currently available are not regularized for non-invasive glucose measurement or oximetry.
A company therefore cannot rely on a wellness-product positioning while simultaneously making diagnostic or clinically framed claims that imply a regulated medical use.
Intended purpose should be reviewed across the entire user-facing product
The boundary is not limited to smart rings.
Apps, watches, wristbands, and other wearables can face the same issue where hardware capabilities, software outputs, user interfaces, instructions, and promotional content collectively communicate a medical purpose.
For Brazil, companies should therefore evaluate not only device design but also the intended purpose presented in packaging, instructions, websites, app screens, advertising, and distributor materials.
What companies can check
- Review Brazil-facing marketing for language that turns wellness information into diagnostic or clinical-monitoring claims.
- Where glucose, oxygen saturation, or other clinical parameters are claimed, confirm that the product has the corresponding ANVISA regularization.
- Align intended purpose across the app, packaging, instructions, website, and advertising.
- Add regulatory review to marketing-claim approval for products that sit near the consumer-wellness / medical-device boundary.
- Monitor distributors and resellers for medical claims that exceed the manufacturer’s approved positioning.
The update is not a new regulation, but it gives companies a clear view of ANVISA’s enforcement boundary. For wearable and digital-health products, what the product is claimed to do can be as important as the sensor technology itself.
Sources
- Primary official sourceAnéis inteligentes NÃO devem ser usados para diagnosticar doenças (opens in a new tab)Brazilian Health Regulatory Agency
- Supporting sourceDispositivos Médicos (opens in a new tab)Brazilian Health Regulatory Agency